Axsome Therapeutics. has filed a patent for a solid dosage form that combines an active pharmaceutical ingredient (API), a cyclodextrin, and a bicarbonate. The composition is designed for oral administration and aims to improve the bioavailability and pharmacokinetics of the drug, particularly for pain treatment. GlobalData’s report on Axsome Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Axsome Therapeutics, Antibody-conjugate nanoparticles was a key innovation area identified from patents. Axsome Therapeutics's grant share as of September 2023 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Solid dosage form comprising api, cyclodextrin, and bicarbonate
A recently filed patent (Publication Number: US20230285306A1) describes a solid dosage form that includes an active pharmaceutical ingredient (API), a cyclodextrin, and a bicarbonate. The patent claims that this solid dosage form has several advantages compared to reference dosage forms.
According to the claims, the solid dosage form is an oral dosage form that has a shorter Tmax (time to reach maximum concentration) of the API in a human being compared to a reference dosage form that does not contain a cyclodextrin or a bicarbonate. This suggests that the solid dosage form may have a faster onset of action.
Additionally, the solid dosage form is said to have improved dissolution of the API in a human being compared to reference dosage forms that do not contain a cyclodextrin or a bicarbonate. This implies that the API is more readily available for absorption in the body, potentially leading to enhanced therapeutic effects.
Furthermore, the solid dosage form claims to have improved bioavailability of the API compared to reference dosage forms that do not contain a cyclodextrin or a bicarbonate. Bioavailability refers to the extent and rate at which a drug reaches the systemic circulation and is available to produce its desired effects. Improved bioavailability suggests that the solid dosage form may result in higher and more consistent drug levels in the body.
The patent also specifies that the cyclodextrin used in the solid dosage form is a sulfobutylether ß-cyclodextrin (SBEßCD) with a specific number of sulfobutyl ether groups per molecule of ß-cyclodextrin. The dosage form may contain varying amounts of SBEßCD, ranging from about 100 mg to about 500 mg.
Similarly, the bicarbonate component of the solid dosage form can be either sodium bicarbonate or potassium bicarbonate. The dosage form may contain about 400 mg to about 1000 mg of the bicarbonate, depending on the specific formulation.
The solid dosage form can be in the form of a bilayer tablet or a monolayer tablet, and it is intended for oral administration directly to a human being. It is also indicated for the treatment of pain, inflammation, or related conditions.
Overall, this patent describes a solid dosage form that combines an API, a cyclodextrin, and a bicarbonate, claiming improved pharmacokinetic properties compared to reference dosage forms.
To know more about GlobalData’s detailed insights on Axsome Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
